Code No. | K0215-3 | |
Anti-HLA-E (Human) mAb | ||
Price | ¥33,000 | |
Size | 100 µL (1 mg/mL) | |
Availability (in Japan) | 10 or more
(In Japan at 00:05, Feb 12, 2025 in JST) |
|
Clonality | Monoclonal | |
Clone | 4D12 | |
Isotype (Immunized Animal) |
Mouse IgG1 | |
Applications | FCM 10 µg/mL (final concentration) IH* reported. (PMID: 20947660) |
|
Immunogen (Antigen) |
This antibody was established by immunization of HLA-B27 transgenic mice with HLA-E protein. | |
Reactivity [Gene ID] | Human |
|
Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | |
Storage temp. | -20°C | |
Conjugate | Unlabeled | |
Manufacturer | MBL | |
Background | HLA-E (human leucocyte antigen-E) is a conserved class I major histocompatibility molecule. It binds to the leader peptide derived from the polymorphic classical MHC molecules HLA-A, HLA-B and HLA-C. This peptide binding stabilizes the HLA-E protein and allows it to migrate to the cell surface. HLA-E then interacts with CD94/NKG2A receptors on natural killer cells. This interaction inhibits natural killer cell-mediated lysis of cells displaying HLA-E. In virally infected or tumor cells, down-regulation of HLA-A, HLA-B and HLA-C production prevents stabilization of HLA-E by the leader peptide. Under these circumstances, HLA-E is degraded before it reaches the cell surface and the cell is then vulnerable to lysis by natural killer cells. | |
Related products | K0126-3 Anti-HLA-E (Human) mAb K0208-3 Anti-HLA-A24 (Human) mAb K0208-4 Anti-HLA-A24 (Human) mAb-FITC K0208-5 Anti-HLA-A24 (Human) mAb-PE K0208-A48 Anti-HLA-A24 (Human) mAb-Alexa Fluor™ 488 K0209-3 Anti-HLA-A24 (Human) mAb K0209-4 Anti-HLA-A24 (Human) mAb-FITC K0209-5 Anti-HLA-A24 (Human) mAb-PE |
|
Product category | Research area:Immunology Cell surface antigens | |
Data | ![]() |
|
Citations | Flow Cytometry
Immunohistochemistry
|